We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) ( n=337) versus chemotherapy ( n=271) or autologous HSCT (autoHSCT) ( n=152) in 760 patients aged 40–60 years with AML in CR1. The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |